Inside every tumor,
hidden cells resist treatment
Deep within solid tumors, cancer cells adapt to survive without oxygen. These hypoxic cells resist radiotherapy, chemotherapy, and immunotherapy — and they are a major reason tumors come back.
Kripthonite Therapeutics is developing a first-in-class treatment designed specifically to address this unmet medical need.
PH1154 targets what others can't reach
Our lead compound PH1154 activates only in low-oxygen environments. It penetrates deep into the tumor core, selectively destroying hypoxic cancer cells while leaving healthy tissue unharmed.
Now conventional treatments can finish the job
With hypoxic cells eliminated, standard therapies become dramatically more effective. Radiotherapy, chemotherapy, and immunotherapy can now target the remaining cancer cells without resistance.
Tumor eradication
Increased survival - challenging with conventional therapies alone.
By targeting hypoxic cells, we open the door to outcomes that current therapies can't achieve on their own.
Conventional treatment alone
Radiotherapy, chemotherapy, and immunotherapy can shrink tumors dramatically. But hypoxic cancer cells survive in low-oxygen zones where these treatments lose their effect. Over time, these resistant cells regrow the tumor — leading to relapse.
With HTMC treatment first
PH1154 eliminates hypoxic cancer cells and thereby primes the tumor microenvironment for effective standard therapy. With the most resistant cancer cells removed, conventional treatments can finish what they started. The result is a real path to improved quality of life and increased survival.
SAVING LIVES BY ELIMINATING HYPOXIC CANCER CELLS
Pioneering hypoxia-targeted cancer therapy
Kripthonite Therapeutics is a Danish biotech company developing a new class of treatments that target hypoxic tumor cells — the cancer cells that survive conventional treatment.
Our lead compound PH1154 is progressing toward clinical trials, with strong preclinical results showing potent efficacy in combination with radiotherapy.
Partner with us
Kripthonite Therapeutics are seeking partnerships with strong players in oncology who share our mission: bringing truly curative treatments to patients with solid tumors.
